Table 2 Comparison of methylation of 7 miR CpG islands in 112 GC samples from patients with various clinicopathological characteristics

Age

≤60 (n = 49)

46.9 ^a

21 [14–38]

68.8

35 [31–42]

95.9

34 [16–48] ^b

62.5

5 [2–16]

92.9

49 [43–55]

54.3

3 [2–14]

65.1

9 [5–27]

>60 (n = 63)

73.0

33 [18–44]

61.0

36 [30–44]

93.3

47 [29–61]

54.2

10 [3–23]

87.7

48 [40–56]

38.3

3 [2–14]

72.9

10 [5–17]

Sex

Male (n = 80)

61.2

31 [14–45]

62.7

35 [30–42]

96.1

40 [24–54]

53.8

7 [3–18]

88.4

48 [40–56]

44.6

3 [2–7]

69.9

9 [5–17]

Female (n = 32)

62.5

27 [17–36]

68.8

41 [30–43]

90.6

43 [18–54]

69.0

8 [2–26]

93.3

51 [46–55]

46.9

8 [2–19]

69.0

12 [5–22]

Preoperative chemotherapy

No (n = 100)

63.0

32 [16–44]

63.2

35 [30–43]

93.8

39 [23–56]

58.9

7 [3–18]

91.0

49 [41–56]

44.7

4 [2–16]

69.6

9 [5–19]

Yes (n = 9)

55.6

21 [12–31]

66.7

37 [31–54]

100

49 [30–53]

44.4

5 [2–16]

71.4

49 [42–76]

44.4

2 [2–4]

57.1

13 [10–24]

Location

Cardiac (n = 34)

64.7

37 [21–47]

65.6

43 [35–51] ^b

90.9

49 [28–61] ^b

57.6

8 [3–23]

75.0 ^d

43 [38–52]

31.2

3 [1–8]

64.5

9 [4–17]

Non-cardiac (n = 78)

60.3

28 [14–42]

64.0

34 [30–42]

96.1

38 [20–52]

58.1

6 [3–18]

97.0

50 [42–56]

51.4

3 [2–16]

71.8

10 [5–21]

Differentiation

Well/Mod. (n = 29)

72.4 ^a

27 [9–44]

69.0

37 [30–50]

86.2

45 [31–53]

44.4

9 [3–16]

84.6

53 [42–58]

40.7

3 [2–4]

73.1

9 [4–17]

Poor (n = 78)

56.4

31 [19–42]

63.0

35 [30–42]

97.3

38 [22–55]

64.0

6 [3–19]

91.3

48 [40–54]

45.9

3 [2–14]

66.2

10 [5–21]

Vascular embolus

No (n = 60)

65.0

26 [14–45]

70.2

35 [31–43]

89.7 ^d

45 [26–59]

55.0

10 [3–19] ^c

92.5

50 [42–57]

51.7

3 [2–13]

70.2

9 [5–20]

Yes (n = 49)

59.2

31 [19–39]

55.3

37 [30–43]

100

39 [22–50]

65.9

3 [2–11]

86.0

48 [40–53]

40.0

5 [2–20]

66.7

11 [5–20]

pTNM stage

I-II (n = 40)

70.0

30 [14–47]

67.6

37 [33–45]

89.7 ^d

46 [35–59]

59.0

10 [3–28] ^c

91.9

49 [41–56]

51.3

3 [2–8]

64.1

9 [5–19]

III-IV (n = 59)

59.3

30 [19–40]

60.3

39 [32–43]

100

40 [22–53]

58.2

4 [2–17]

87.8

49 [41–54]

41.8

5 [2–20]

70.0

12 [5–28]

Depth of invasion

T_1-2 (n = 25)

68.0

34 [11–52]

72.7

36 [31–44]

84.0 ^e

48 [36–59]

73.9

10 [3–21]

86.4

52 [44–56]

47.8

2 [2–4]

70.8

9 [3–19]

T₃ (n = 53)

62.3

28 [17–41]

58.5

35 [30–43]

96.1

43 [28–53]

49.0

7 [2–24]

91.3

46 [36–56]

48.0

5 [2–18]

68.8

10 [5–18]

T₄ (n = 25)

60.0

30 [16–38]

62.5

42 [33–44]

100

31 [15–53]

66.7

5 [2–17]

90.9

49 [41–55]

36.0

8 [3–20]

66.7

14 [5–32]

Lymph node metastasis

N₀ (n = 57)

68.4

26 [13–47]

67.3

35 [32–43]

89.1 ^d

45 [22–58]

61.8

10 [3–20]

90.6

53 [43–57] ^c

46.4

2 [2–10]

67.3

9 [5–19]

N_1-3 (n = 51)

56.9

31 [21–41]

58.3

39 [30–44]

100

39 [26–52]

58.3

4 [2–16]

88.1

45 [37–52]

47.8

5 [2–20]

69.8

11 [5–23]

Distant metastasis

M₀ (n = 77)

67.5 ^a

30 [14–44]

64.4

37 [32–43]

92.0

42 [24–56]

60.0

8 [3–19]

91.5

49 [41–56]

46.7

3 [2–13]

68.1

9 [5–17] ^c

M₁ (n = 31)

51.6

30 [21–40]

60.0

36 [30–43]

100

43 [24–53]

60.7

6 [2–17]

83.3

49 [40–53]

48.1

6 [3–20]

69.2

15 [9–28]